← Patent-cliff monitor small molecule CRENESSITY CRINECERFONT
Loss of exclusivity January 2043 latest FDA-listed patent expiry
Drug detail Brand name CRENESSITY Active ingredient CRINECERFONT Strength 100MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval December 2024 Marketing status RX
Listed patents Patent Expires Type 12582634 January 2043 substance 12128033 June 2041 substance 10905690 January 2035 use U-4049 11311544 January 2035 use U-4049 11730739 January 2035 use U-4049
Regulatory exclusivity Code Expires ODE-503 December 2031 NCE December 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.